Fennec Pharmaceuticals Inc
FENC
Get informed when a big investor buys or sells
+ FollowMarket Cap$283.8M
Close$
$7.58
17.1% downside
Current Fair Value
17.1% downsideOvervalued by 17.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $283.80 Million |
|---|---|
| Enterprise Value | $243.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.36 |
| Beta | 0.91 |
| Outstanding Shares | 34,336,000 |
Return
| Return on Equity | -23.39% |
|---|---|
| Return on Assets | -12.27% |
| Return on Invested Capital | -9.61% |
Valuation & Multiples
| P/E Ratio | -40.71 |
|---|---|
| PEG | 34.72 |
| Price to Sales | 9.14 |
| Price to Book Ratio | 9.14 |
| Enterprise Value to Revenue | 4.76 |
| Enterprise Value to EBIT | -40.79 |
| Enterprise Value to Net Income | -28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$13.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$16.39 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 22,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.69%▲ 0.98% |
|---|---|
| Total Invested | $99.64M▼ 16.72% |
| Investors Holding | 91▼ 5.00% |
ESG Score
No data
About Fennec Pharmaceuticals Inc
CEO: Rostislav Raykov